With its destructive power, Hurricane Maria revealed the fragility of the global pharmaceutical supply chain when it struck Puerto Rico, a major drug manufacturing hub, earlier this year. How can US regulatory bodies mitigate the impact climate change, and the resulting “super storms”, has on drug availability?